EC
JBIO icon

EntryPoint Capital’s Jade Biosciences JBIO Stock Holding History

EntryPoint Capital’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-89
Closed -$92.4K – 1403
2024
Q1 		$92.4K Sell
89
-86
-49% -$65.7K 0.08% 471
2023
Q4 		$139K Buy
+175
New +$89.2K 0.13% 223

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

EntryPoint Capital's JBIO Position: Q2 2024 in Review

EntryPoint Capital sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 89 shares — an estimated $92.4K sold.

EntryPoint Capital first reported a position in JBIO in Q4 2023 and held it in 2 quarters. The position peaked at $139K in Q4 2023. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • EntryPoint Capital reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 89 Jade Biosciences shares in Q2 2024, an estimated $92.4K.
  • EntryPoint Capital first reported a position in Jade Biosciences in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Jade Biosciences position peaked at $139K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.